Another day, another psychedelic trial with missing placebo response (
tinyurl.com/3pzpxpac), this time with 5-MeO-DMT. In this case the patients actually got WORSE in the placebo group. In the past month, 4 high profile psychedelic trials came out, all on treatment-resistant depression, all showing the same phenomena: there is virtually no placebo response in the control arm of psychedelic studies, see image below (negative values indicate improvement as you want less depression):
A: 5-meo vs PL, placebo response is 0.3 MADRS units (
tinyurl.com/3pzpxpac)
B: psilocybin vs active PL (nicotinamide), placebo response is -1.5 MADRS units (
tinyurl.com/yueyphn5)
C: psilocybin vs PL, placebo response is -1.2 MADRS units (COMP005
tinyurl.com/cjjmh8x7)
D: psilocybin vs active PL (1mg psilocybin), placebo response -3.7 MADRS units (COMP006
tinyurl.com/cjjmh8x7)
The typical placebo response in trials on major depression of antidepressants is -9 MADRS points (
shorturl.at/fwTNs). The typical placebo response in trials on TRD with ketamine -7 MADRS points (
shorturl.at/ZS0QQ).